Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged.

Area of Science:

• Oncology
• Immunology
• Neuro-oncology

Background:

• Glioblastoma multiforme (GBM) is an aggressive brain cancer with limited treatment options.
• Immunotherapy, encompassing checkpoint inhibitors, CAR T-cells, vaccines, and oncolytic viruses, shows promise for GBM treatment.
• Current GBM treatment protocols lack standardized immunotherapy integration.

Purpose of the Study:

• To review current immunotherapy strategies for glioblastoma multiforme.
• To highlight the challenges and necessity of individualized multimodal immunotherapies.
• To emphasize the need for innovative methods to assess and implement complex immunotherapies.

Main Methods:

• Review of existing immunotherapy approaches for GBM, including checkpoint inhibitors, adoptive cell therapies (CAR T-cells), vaccines, antibody-mediated delivery, and oncolytic viral therapy.
• Discussion of the complexities in standardizing immunotherapy trials, requiring stratification by prognostic factors (e.g., RPA, MGMT methylation, epigenetics, tumor microenvironment, immune status).
• Presentation of data on individualized multimodal immunotherapies for GBM.

Main Results:

• Immunotherapies, including checkpoint inhibitors, CAR T-cells, vaccines, and oncolytic viruses, are viable GBM treatment strategies.
• Individualized multimodal immunotherapies offer a flexible and rational approach for long-term tumor control.
• Standardization of immunotherapy trials is challenging due to patient heterogeneity and dynamic disease progression.

Conclusions:

• Immunotherapies should be integrated into standard GBM treatment protocols.
• Individualized multimodal immunotherapies are optimal for GBM but require advanced assessment tools.
• Innovative methods are crucial for evaluating complex immunotherapies and accelerating their clinical adoption.